Are genetic and sporadic Parkinson's disease patients equally susceptible to develop dementia?

Journal of the Neurological Sciences

Volumn 289, Issue 1-2, 2010, Pages 23-26

  Inzelberg, Rivka ^a   Polyniki, Anna ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

Author keywords

ApoE; Dementia; Genetic; Parkin; Parkinson's disease; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; APOLIPOPROTEIN E; LEUCINE RICH REPEAT KINASE 2; PARKIN;

ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; GENETIC ASSOCIATION; GROUPS BY AGE; HUMAN; LEWY BODY; ONSET AGE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL;

ALPHA-SYNUCLEIN; DEMENTIA; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 74149086440     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.08.015     Document Type: Article

References (44)

1. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2 (2003) 229-237
2. Farlow M.R., and Cummings J. A modern hypothesis: the distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease. Dement Geriatr Cogn Disord 25 (2008) 301-308
3. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.R., Cook N.R., Herbert L.E., et al. Prevalence of Alzheimer's disease in a community population of older persons higher than previously reported. JAMA 262 (1989) 2551-2556
4. Aarsland D., Andersen K., Larsen J.P., Lolk A., and Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson's disease: an 8-year prospective study. Arch Neurol 60 (2003) 387-837
5. Inzelberg R., Schecthman E., Paleacu D., Zach L., Bonwitt R., Carasso R.L., et al. Onset and progression of disease in familial and sporadic Parkinson's disease. Am J Med Genet 124 (2004) 255-258
6. Polymeropoulos M.H., Lavedan C., Leroy E., et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
7. Spillantini M.G., Schmidt M.L., Lee V.M.-Y., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
8. Singleton A., and Gwinn-Hardy K. Parkinson's disease and dementia with Lewy bodies: a difference in dose?. Lancet 364 (2004) 1105-1106
9. Giasson B.I., Duda J.E., Murray I.V.J., Chen Q., Souza J.M., Hurtig H.I., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 (2000) 985-989
10. Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., et al. Phosphorylation of ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281 (2006) 29739-29752
11. Apaydin H., Ahlskog J.E., Parisi J.E., Boeve B.F., and Dickson D.W. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 59 (2002) 102-112
12. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54 (2000) 1916-1921
13. Nishioka K., Hayashi S., Farrer M.J., Singleton A.B., Yoshino H., Imai H., et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol 59 (2006) 298-309
14. Ahn T.-B., Kim S.Y., Kim J.Y., Park S.-S., Lee D.S., Min H.J., et al. Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology 70 (2008) 43-49
15. Fuchs J., Nilsson C., Kachergus J., Munz M., Larsson E.-M., Schule B., et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68 (2007) 916-922
16. Beyer K., Domingo-Sabat M., Lao J.I., Carrato C., Ferrer I., and Ariza A. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 9 (2008) 15-23
17. Gwinn-Hardy K., Mehta N.D., Farrer M., Maraganore D., Muenter M., Yen S.-H., et al. Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropath 99 (2000) 663-672
18. Farrer M., Kachergus J., Forno L., Lincoln S., Wang D.-S., Hulihan M., et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55 (2004) 174-179
19. Spellman G.G. Report of familial cases of parkinsonism: evidence of a dominant trait in a patient's family. JAMA 179 (1962) 372-374
20. Obi T., Nishioka K., Ross O.A., Terada T., Yamazaki K., Sugiura A., et al. Clinicopathological study of a SNCA duplication patient with Parkinson disease and dementia. Neurology 70 (2008) 238-241
21. Kitada T., Asakawa S., Hattori N., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
22. Lucking CB, Durr A, Bonifati V, XXXet al. Association between early-onset Parkinson's disease and mutations in the parkin gene. New Eng J Med 2000;342: 1560-7.
23. Nisipeanu P., Inzelberg R., Blumen S.C., Carasso R.L., Hattori N., Matsumine H., et al. Autosomal recessive juvenile parkinsonism in a Jewish Yemenite kindred: Mutation of Parkin gene. Neurology 53 (1999) 1602-1604
24. Nisipeanu P., Inzelberg R., Abo Mouch S., Carasso R.L., Blumen S.C., Zhang J., et al. Parkin gene causing benign autosomal recessive juvenile parkinsonism. Neurology 56 (2001) 1573-1575
25. Inzelberg R., Hattori N., Nisipeanu P., Abo Mouch S., Blumen S.C., Carasso R.L., et al. Camptocormia, axial dystonia and parkinsonism: phenotypic heterogeneity of a parkin mutation. Neurology 60 (2003) 1393-1394
26. Hayashi S., Wakabayashi K., Ishikawa A., Nagai H., Saito M., Maruyama M., et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 15 (2000) 884-888
27. Van de Warrenburg B.P.C., Lammens M., Lucking C.B., Denefle P., Wesseling P., Booij J., et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin disease. Neurology 56 (2001) 553-557
28. Ephraty L., Porat O., Israeli D., Cohen O.S., Tunkel O., Yael S., et al. Neuropsychiatric and cognitive features in autosomal-recessive early parkinsonism due to PINK1 mutations. Mov Disord 22 (2007) 566-569
29. Steinlechner S., Stahlberg J., Völkel B., Djarmati A., Hagenah J., Hiller A., et al. Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations. J Neurol Neurosurg Psychiatry 78 (2007) 532-535
30. Kubo S., Hattori N., and Mizuno Y. Recessive Parkinson's disease. Mov Disord 21 (2006) 885-893
31. Khan N.L., Graham E., Critchley P., Schrag A.E., Wood N.W., Lees A.J., et al. Parkin disease: a phenotypic study of a large case series. Brain 126 (2003) 1279-1292
32. Lindholm E., Ekholm B., Shaw S., Jalonen P., Johansson G., Pettersson U., et al. A schizophrenia-susceptibility locus at 6q25, in one of the world's largest reported pedigrees. Am J Hum Genet 69 (2001) 96-105
33. Albanese A., and Valente E.M. M, Bellacchio E, Elia AE, Dallapiccola B. The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology 64 (2005) 1958-1960
34. Li Y., Tomiyama H., Sato K., Hatano Y., Yoshino H., Atsumi M., et al. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. Neurology 64 (2005) 1955-1957
35. Funayama M., Li Y., Tsoi T.H., Lam C.W., Ohi T., Yazawa S., et al. Familial Parkinsonism with digenic parkin and PINK1 mutations. Mov Disord 23 (2008) 1461-1465
36. Tomiyama H., Li Y., Funayama M., Hasegawa K., Yoshino H., Kubo S.I., et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord 21 (2006) 1102-1108
37. Ross O.A., Toft M., Whittle A.J., Johnson J.L., Papapetropoulos S., Mash D.C., et al. LRRK2 and Lewy body disease. Ann Neurol 59 (2006) 388-393
38. Spanaki C., Latsoudis H., and Plaitakis A. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 67 (2006) 1518-1519
39. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 92-93
40. Jasinska-Myga B., Opala G., Goetz C.G., Tustanowski J., Ochudlo S., Gorzkowska A., et al. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol 64 (2007) 261-265
41. Inzelberg R., Paleacu D., Chapman J., and Korczyn A.D. Apolipoprotein E and Parkinson's disease. Ann Neurol 44 (1998) 294
42. Paleacu D, Inzelberg R, Chapman J, Orlov Y, Asherov A, Korczyn AD. Apolipoprotein E ε4 allele does not influence the development of dementia in Parkinsonian patients. In: Fisher IH, Yashida M, editors, Advances in Behavioral Biology, New York, Plenum Press,1998;47:817-821
43. Inzelberg R., Chapman J., Treves T.A., Asherov A., Kipervasser S., Hilkewicz O., et al. Apolipoprotein E4 in Parkinson's disease and dementia: new data and meta-analysis of published studies. Alz Disease Assoc Disord 12 (1998) 45-48
44. Camicioli R., Rajput A., Rajput M., Reece C., Payami H., and Hao C. Apolipoprotein E4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations. Mov Disord. 20 (2005) 989-994